BamSEC and AlphaSense Join Forces
Learn More

Oragenics Inc.

NYSE American: OGEN    
Share price (12/26/24): $0.39    
Market cap (12/26/24): $4.787 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 44 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 37 pages Oragenics, Inc. Common Stock (Par Value $0.001 Per Share) At-The-Market Issuance Sales Agreement
12/34/56
EX-10.1
from 8-K 20 pages Executive Employment Agreement
12/34/56
EX-10.6
from 10-Q 32 pages [***] Portions of This Exhibit Have Been Redacted Pursuant to Item 601(b)(2) of Regulations S-K as (I) Not Material and (II) Likely to Cause Competitive Harm if Publicly Disclosed. the Company Hereby Undertakes to Furnish Unredacted Copies of This Exhibit Upon Request by the Securities and Exchange Commission; Provided, However, That the Company May Request Confidential Treatment Pursuant to Rule 24b-2 of the Exchange Act for Such Unredacted Copies of This Exhibit
12/34/56
EX-10.1
from 8-K 5 pages Form of Oragenics, Inc. Restricted Stock Award Grant Notice
12/34/56
EX-10.1
from 8-K 31 pages Securities Purchase Agreement
12/34/56
EX-10.7
from 10-Q 2 pages [***] Portions of This Exhibit Have Been Redacted Pursuant to Item 601(b)(2) of Regulations S-K as (I) Not Material and (II) Likely to Cause Competitive Harm if Publicly Disclosed. the Company Hereby Undertakes to Furnish Unredacted Copies of This Exhibit Upon Request by the Securities and Exchange Commission; Provided, However, That the Company May Request Confidential Treatment Pursuant to Rule 24b-2 of the Exchange Act for Such Unredacted Copies of This Exhibit
12/34/56
EX-10.5
from 10-Q 31 pages [***] Portions of This Exhibit Have Been Redacted Pursuant to Item 601(b)(2) of Regulations S-K as (I) Not Material and (II) Likely to Cause Competitive Harm if Publicly Disclosed. the Company Hereby Undertakes to Furnish Unredacted Copies of This Exhibit Upon Request by the Securities and Exchange Commission; Provided, However, That the Company May Request Confidential Treatment Pursuant to Rule 24b-2 of the Exchange Act for Such Unredacted Copies of This Exhibit
12/34/56
EX-10.1
from 8-K 19 pages Executive Employment Agreement
12/34/56
EX-10.4
from 10-Q 2 pages This Is an Amending Agreement (Hereinafter Referred to as the “Amendment #4”) Between: National Research Council of Canada (Called “Nrc” ) a Departmental Corporation” Forming Part of the Government of Canada, Which Corporation Was Created by Act of Parliament, R.S.C. 1985, C. N-15 Whose Head Office Address Is: 1200 Montreal Road, Ottawa, Ontario K1a 0r6 Canada Human Health Therapeutics (Hht) Research Centre Located At: 6100 Royalmount Avenue, Montreal, Quebec H4p 2r2 Canada
12/34/56
EX-10.1
from 8-K 20 pages Executive Employment Agreement
12/34/56
EX-10.7
from 10-K 2 pages Amended Annex a – Stable Cells
12/34/56
EX-10.6
from 10-K 3 pages This Is an Amending Agreement (The “Agreement”) Between: National Research Council of Canada (Called “Nrc”) a Departmental Corporation” Forming Part of the Government of Canada, Which Corporation Was Created by Act of Parliament, R.S.C. 1985, C. N-15 Whose Head Office Address Is: 1200 Montreal Road, Ottawa, Ontario K1a 0r6 Canada Human Health Therapeutics (Hht) Research Centre Located At: 6100 Royalmount Avenue, Montreal, Quebec H4p 2r2 Canada Scientific Contacts: Yves Durocher – Email: YVES.DUROCHER@CNRC-NRC.GC.CA Freya Vercauteren – Email: FREYA.VERCAUTEREN@CNRC-NRC.GC.CA
12/34/56
EX-10.4
from 8-K 7 pages Oragenics, Inc. 2021 Equity Incentive Plan Notice of Grant of Stock Options and Stock Option Award Agreement
12/34/56
EX-10.3
from 8-K 8 pages Oragenics, Inc. 2021 Equity Incentive Plan Notice of Grant of Stock Options and Stock Option Award Agreement
12/34/56
EX-10.2
from 8-K 7 pages Oragenics, Inc. 2021 Equity Incentive Plan Notice of Grant of Stock Options and Stock Option Award Agreement
12/34/56
EX-10.1
from 8-K 25 pages Oragenics, Inc. 2021 Equity Incentive Plan
12/34/56
EX-10
from 10-Q 25 pages [***] Portions of This Exhibit Have Been Redacted Pursuant to Item 601(b)(2) of Regulations S-K as (I) Not Material and (II) Likely to Cause Competitive Harm if Publicly Disclosed. the Company Hereby Undertakes to Furnish Unredacted Copies of This Exhibit Upon Request by the Securities and Exchange Commission; Provided, However, That the Company May Request Confidential Treatment Pursuant to Rule 24b-2 of the Exchange Act for Such Unredacted Copies of This Exhibit
12/34/56
EX-10.1
from 10-K 44 pages Amended and Restated Exclusive Channel Collaboration Agreement
12/34/56
EX-10.1
from 8-K 32 pages Form of Securities Purchase Agreement
12/34/56